Motley Fool Asset Management LLC Grows Holdings in CVS Health Corporation $CVS

Motley Fool Asset Management LLC increased its position in shares of CVS Health Corporation (NYSE:CVS) by 30.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 129,763 shares of the pharmacy operator’s stock after buying an additional 30,027 shares during the period. Motley Fool Asset Management LLC’s holdings in CVS Health were worth $10,298,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CVS. Norges Bank purchased a new stake in CVS Health during the 4th quarter worth $1,666,265,000. Wellington Management Group LLP increased its stake in CVS Health by 391.6% during the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock worth $477,273,000 after buying an additional 5,042,816 shares during the period. Amundi increased its stake in CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares during the period. Capital Research Global Investors increased its stake in CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in CVS Health by 70.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after buying an additional 2,188,307 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CVS. Mizuho lifted their price target on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Monday. Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Leerink Partners reissued an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. TD Cowen raised their price objective on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Sanford C. Bernstein lifted their price target on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.68.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: UBS raised its price target on CVS to $115 from $100 and reiterated a buy rating, signaling confidence that the shares can still move higher. UBS adjusts price target on CVS Health to $115 from $100, maintains buy rating
• Positive Sentiment: The company continues to highlight growth initiatives, including expanded GLP-1 access, new AI and patient-care programs, and a new CFO appointment for its health care delivery business, all of which suggest ongoing investment in operational execution. CVS Health valuation check as GLP-1 access expands and PBM scrutiny intensifies
• Positive Sentiment: CVS also received recognition for technology that improves medication safety and patient care, reinforcing its push to position itself as a broader health services company rather than only a pharmacy chain. CVS Health recognized for technology that improves medication safety and patient care

CVS Health Trading Down 0.1%

Shares of NYSE:CVS opened at $96.97 on Wednesday. The company has a market cap of $123.73 billion, a PE ratio of 42.72, a P/E/G ratio of 0.95 and a beta of 0.62. The company’s 50-day moving average price is $85.19 and its 200 day moving average price is $80.32. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $98.43. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.